1. Malignant brain cancers, such as glioblastoma, are highly heterogeneous and aggressive and have a high chance of relapse.
2. Brain tumour initiating cells (BTICs) are thought to be the “root” of tumour occurrence and are responsible for the growth and relapse of tumours.
3. NR2E1 and LSD1 both play important roles in glioblastoma, so this article investigates whether BTICs employ the same NR2E1-LSD1 mechanism, as in NSCs, to regulate BTIC proliferation.
The article is generally reliable and trustworthy in its reporting of research findings on the potential role of NR2E1-LSD1 in regulating BTIC proliferation. The authors provide a comprehensive overview of the current understanding of malignant brain cancers, BTICs, NR2E1 and LSD1, which serves as a strong foundation for their research question. The methods used to conduct their experiments are clearly outlined with sufficient detail for readers to understand how they arrived at their conclusions. Furthermore, the authors provide evidence from multiple sources to support their claims throughout the article.
However, there are some areas where the article could be improved upon. For example, while the authors discuss potential risks associated with targeting NR2E1-LSD1 for brain tumour therapy, they do not explore any possible counterarguments or alternative approaches that could be taken instead. Additionally, while they provide evidence from multiple sources to support their claims throughout the article, it is unclear if any bias exists in terms of which sources were chosen or how much weight was given to each source when making conclusions about their findings. Finally, while the authors discuss potential implications for clinical therapies based on their findings, they do not provide any concrete recommendations or suggestions on how these findings can be applied in practice.